These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7. Ramachandran PS; Boudreau RL; Schaefer KA; La Spada AR; Davidson BL Mol Ther; 2014 Sep; 22(9):1635-42. PubMed ID: 24930601 [TBL] [Abstract][Full Text] [Related]
5. AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model. Niewiadomska-Cimicka A; Fievet L; Surdyka M; Jesion E; Keime C; Singer E; Eisenmann A; Kalinowska-Poska Z; Nguyen HHP; Fiszer A; Figiel M; Trottier Y Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673939 [TBL] [Abstract][Full Text] [Related]
6. Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration. Furrer SA; Mohanachandran MS; Waldherr SM; Chang C; Damian VA; Sopher BL; Garden GA; La Spada AR J Neurosci; 2011 Nov; 31(45):16269-78. PubMed ID: 22072678 [TBL] [Abstract][Full Text] [Related]
7. Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration. Garden GA; La Spada AR Cerebellum; 2008; 7(2):138-49. PubMed ID: 18418675 [TBL] [Abstract][Full Text] [Related]
8. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897 [TBL] [Abstract][Full Text] [Related]
9. SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Yvert G; Lindenberg KS; Devys D; Helmlinger D; Landwehrmeyer GB; Mandel JL Hum Mol Genet; 2001 Aug; 10(16):1679-92. PubMed ID: 11487572 [TBL] [Abstract][Full Text] [Related]
10. Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7. Furrer SA; Waldherr SM; Mohanachandran MS; Baughn TD; Nguyen KT; Sopher BL; Damian VA; Garden GA; La Spada AR Hum Mol Genet; 2013 Mar; 22(5):890-903. PubMed ID: 23197655 [TBL] [Abstract][Full Text] [Related]
11. Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7. Curtis HJ; Seow Y; Wood MJA; Varela MA Nucleic Acids Res; 2017 Jul; 45(13):7870-7885. PubMed ID: 28575281 [TBL] [Abstract][Full Text] [Related]
12. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. Fiszer A; Olejniczak M; Switonski PM; Wroblewska JP; Wisniewska-Kruk J; Mykowska A; Krzyzosiak WJ BMC Mol Biol; 2012 Mar; 13():6. PubMed ID: 22397573 [TBL] [Abstract][Full Text] [Related]
13. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629 [TBL] [Abstract][Full Text] [Related]
14. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Palhan VB; Chen S; Peng GH; Tjernberg A; Gamper AM; Fan Y; Chait BT; La Spada AR; Roeder RG Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8472-7. PubMed ID: 15932940 [TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Brusco A; Gellera C; Cagnoli C; Saluto A; Castucci A; Michielotto C; Fetoni V; Mariotti C; Migone N; Di Donato S; Taroni F Arch Neurol; 2004 May; 61(5):727-33. PubMed ID: 15148151 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. Ohnishi Y; Tamura Y; Yoshida M; Tokunaga K; Hohjoh H PLoS One; 2008 May; 3(5):e2248. PubMed ID: 18493311 [TBL] [Abstract][Full Text] [Related]
17. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684 [TBL] [Abstract][Full Text] [Related]
18. Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease. Gao Y; Zu T; Low WC; Orr HT; McIvor RS Cell Transplant; 2008; 17(7):723-34. PubMed ID: 19044200 [TBL] [Abstract][Full Text] [Related]
19. Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model. Yu X; Ajayi A; Boga NR; Ström AL J Mol Neurosci; 2012 Jun; 47(2):219-33. PubMed ID: 22367614 [TBL] [Abstract][Full Text] [Related]
20. A novel central nervous system-enriched spinocerebellar ataxia type 7 gene product. Einum DD; Clark AM; Townsend JJ; Ptacek LJ; Fu YH Arch Neurol; 2003 Jan; 60(1):97-103. PubMed ID: 12533095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]